ITK and B-cell chronic lymphocytic leukemia: Since ibrutinib can also inhibit ITK (44), we speculate that the improved CAR-T cell therapeutic effects in ibrutinib-treated CLL patients are in part due to the inhibition of ITK in CAR-T cells.